Thrombin Generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban

• Published in: Journal of thrombosis and thrombolysis 2021, Vol.51 (1), p.47-57
• Main Authors: Duarte, Rita Carolina Figueiredo, Rios, Danyelle Romana Alves, Figueiredo, Estevão Lanna, Caiaffa, José Raymundo Sollero, Silveira, Francisco Resende, Lanna, Rodrigo, Alves, Luan Carlos Vieira, Martins, Gabriela Lopes, Reis, Helton José, Reis, Edna Afonso, Ferreira, Cláudia Natália, Sternick, Eduardo Back, Campos, Fernanda Magalhães Freire, das Graças Carvalho, Maria
• Format: Article
• Language: English
• Subjects: Anticoagulants; Cardiac arrhythmia; Cardiology; Endothelium; Fibrillation; Hematology; Hemostasis; Medicine; Medicine & Public Health; Microparticles; Monocytes; Platelets; Thrombin; Thromboembolism; Warfarin
• ISSN: 0929-5305; 1573-742X
• DOI: 10.1007/s11239-020-02126-3

Patients with atrial fibrillation (AF) present hyperactivation of both platelets and coagulation leading to a hypercoagulable state which contributes to an increased risk of thromboembolism. Therefore, one of the main strategies for treatment of AF is prevention of these events through the use of oral anticoagulants (OAC). The aim of this study was to evaluate hemostasis as a whole in patients with non-valvular AF undergoing warfarin or rivaroxaban by thrombin generation test (TGT), in addition to monocyte-platelet aggregates (MPA), glycoprotein IIb/IIIa (GPIIb/IIIa), and platelet (PMP) and endothelium (EMP) microparticles, compared to age and sex matched controls. PT/INR for OAC use was also determined. In patients taking OAC, compared to control group, a decrease in TGT ( p  = 0.000 for all parameters) were observed. Patients taking warfarin showed to be more hypocoagulable, presenting lower levels of ETP ( p  = 0.000) and peak ( p  = 0.002) than patients using rivaroxaban. Patients on warfarin use with INR > 3 had also lower levels of ETP ( p  = 0.01) and peak ( p  =  0 .006). A decrease in ETP ( p  = 0.03) and peak ( p  = 0.02) values was also observed in patients using rivaroxaban with PT > 21.4 s. Patients using warfarin ( p  = 0.000) and rivaroxaban ( p  = 0.000) presented lower levels of MPA in relation to control group. It was also observed in patients using warfarin, lower GPIIb/IIIa levels in relation to control group ( p  = 0.011). Patients taking rivaroxaban ( p  = 0.003) and warfarin ( p  = 0.001) had higher PMP levels compared to control group. There was no difference in levels of EMP between the groups ( p  = 0.0536). The present study reinforces the usefulness of OAC in AF, which decisively contribute to a better management of the disease preventing possible complications.